Blog
What Is Theranos's Business Model, Anyway?
There are plenty of ways to win in diagnostics - Theranos just needs to pick one.
Can Businesses Learn 'Superforecasting'? Easier Said Than Done
Business leaders should read Philip Tetlock's new book on analyzing data to predict the future - but whether they'll be able to implement its ideas is far from certain.
Pharma CEOs Should Take A Stand On Egregious Price Increase -- But They Won't
Pharma CEOs have the chance to take the "high ground" on drug pricing in the Turing brouhaha. I'm not holding my breath.
Technology, end-of-life care, and 'Being Mortal'
Atul Gawande's recent book on end-of-life care is inspiring and thought-provoking - and an important must-read for tech experts, entrepreneurs, and investors.
Biotech's R&D Talent Opportunity
Mid-level "leader-doers" make the magic happen in R&D. Here's how to get them.
Pharma's hunt for academic innovation
Pharma overlooks many potentially valuable collaborations by focusing exclusively on the academic "A-list".
Enabling R&D collaborations between academia and pharma
Many academic researchers aren't aware of opportunities to collaborate with pharma R&D organizations - so we created a directory to help them. Check it out!
The case for "biotech paranoia"
Biotechs need to get anxious - really anxious - about how changes in the industry will affect Pharma deal-making.
Drug pricing is the new Big Pharma giant-killer
Is the new contracting deal in hepatitis C a meaningless blip, or the “end of days” for biopharma? (Spoiler alert: "no” and “no”.)
You can't have value-based drug pricing without value
Think you can charge a lot more than generics when your drug is only a little bit better? Think again.